Lv11
30 积分 2024-06-11 加入
Obesity in China: current progress and future prospects
49分钟前
已完结
Tirzepatide Versus Intensified Conventional Care After 2 Years of Treatment in Early Type 2 Diabetes
1个月前
已完结
Disease modifying therapies in diabetes and endocrinology
1个月前
已完结
MA04.02 Nautika1: Clinical Outcomes and Pathologic Regression With Neoadjuvant Alectinib in Resectable Stage IB-IIIB ALK + NSCLC
2个月前
已完结
Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer
2个月前
已完结
Accelerating drug development in breast cancer: New frontiers for ER inhibition
2个月前
已完结
Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial
2个月前
已完结
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2–Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti–Human Epidermal Growth Factor Receptor 2 Therapy
3个月前
已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
3个月前
已完结
Cycling GLP-1 receptor agonist treatment induces therapeutic resistance and increased adiposity
3个月前
已完结
皖公网安备34019202002308
